Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?

Ann Rheum Dis. 2019 Apr;78(4):e23. doi: 10.1136/annrheumdis-2017-212820. Epub 2017 Dec 29.

Authors

Fabrizio Cantini¹, Maurizio Benucci²

Affiliations

¹ Department Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy.
² Rheumatology Clinic, Azienda USL Toscana Centro, Nuovo S Giovanni di Dio Hospital, Florence, Italy.

PMID: 29288210
DOI: 10.1136/annrheumdis-2017-212820

No abstract available

Keywords: ankylosing spondylitis; anti-tnf; psoriatic arthritis; rheumatoid arthritis; treatment.

Publication types

Letter
Comment

MeSH terms

Antirheumatic Agents*
Arthritis, Psoriatic*
Biosimilar Pharmaceuticals*
Consensus
Humans
Rheumatic Diseases*

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals